Evidence map›Paper›PMID 27692812›Full record

ArticleClinical genitourinary cancer2017

Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.

Daniel M Moreira, Lauren E Howard, Katharine N Sourbeer, Hiruni S Amarasekara, Lydia C Chow, Dillon C Cockrell, Connor L Pratson, Brian T Hanyok, William J Aronson, Christopher J Kane and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Head-to-head comparison ofScientific reports · 2022
    Trial
  6. Observational
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. [Cancers · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniel M MoreiraDepartment of Urology, University of Illinois at Chicago, Chicago, IL. Electronic address: moreira@uic.edu.
Lauren E HowardDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC; Urology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Katharine N SourbeerUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Hiruni S AmarasekaraUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Lydia C ChowUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Dillon C CockrellUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Connor L PratsonUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
Brian T HanyokUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, and the Duke Prostate Center, Duke University School of Medicine, Durham, NC.
William J AronsonUrology Section, Department of Surgery, Veterans Affairs Medical Center, Greater Los Angeles, Los Angeles, CA; Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA.
Christopher J KaneDivision of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA.
Martha K TerrisUrology Section, Division of Surgery, Veterans Affairs Medical Centers and Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA.
Christopher L AmlingDivision of Urology, Department of Surgery, Oregon Health and Science University, Portland, OR.
Matthew R CooperbergDepartments of Urology and Epidemiology and Biostatistics, University of California, San Francisco and Urology Section, Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA.
Stephen J FreedlandUrology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
IGF-I: A Nutrition-Regulated Target in Prostate CancerR01CA100938 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COHEN, PINCHAS · 2003 to 2007
$1.7M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA100938
6 · The paper itself

Abstract

objectiveTo identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. PATIENTS AND

methodsWe performed a retrospective analysis of 205 mCRPC men. Overall survival was estimated and plotted using the Kaplan-Meier method. The uni- and multivariable overall survival predictors were evaluated with the Cox proportional hazards model. A nomogram was generated to predict overall survival at 1, 2, 3, and 5 years after mCRPC. Concordance index and calibration plot were obtained.

resultsA total of 170 men (83%) died over a median follow-up of 41 months. In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P < .05). In multivariable analysis, older age, more remote year of mCRPC, greater number of bone metastasis, higher PSA levels, and shorter PSA doubling time at mCRPC diagnosis remained significantly associated with shorter overall survival (all P < .05). On the basis of these variables, a nomogram was generated yielding a concordance index of 0.67 and good calibration.

conclusionThe use of clinical parameter such as age, disease burden, and PSA levels and kinetics can be used to estimate overall survival in mCRPC patients.

Indexed as

AgedAged, 80 and overAge FactorsDisease-Free SurvivalHospital MortalityHospitals, VeteransHumansKallikreinsMaleNeoplasm MetastasisNomogramsProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesSurvival AnalysisUnited StatesKallikreinsKLK3 protein, humanProstate-Specific AntigenDisease-free survivalMortalityProstate cancerProstatectomyProstate-specific antigen

Identifiers

PMID27692812
PMCPMC5536956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.